This study tests a personalized immunotherapy called Vigil in 92 people with advanced ovarian cancer who are currently cancer-free after surgery and chemotherapy. The treatment uses a patient's own tumor cells to train their immune system to fight any remaining cancer cells. The …
Phase: PHASE2 • Sponsor: Gradalis, Inc. • Aim: Disease control
Last updated May 17, 2026 08:04 UTC